MT-0169
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MT-0169, covering 2026-02-24 to 2026-02-24. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease [Phase 1]